Lupin acquires five brands from Italy's Menarini to strengthen therapy portfolio
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), the company says.
Lupin shares hit 52-week high on plans to transfer two APIs, select R&D operations to LMSL
The share price of the company surged as much as 4.08% to hit a 52-week high of ₹1,174.00 in early session.
Lupin shares rise 2% on launching heart drug in Canada
The pharma major’s subsidiary has launched Propranolol LA capsules, 60 mg, 80 mg, 120 mg, and 160 mg, in Canada.
Lupin hits 52-week high on US FDA nod for respiratory drug
The scrip opened a gap-up at ₹834.95 on Wednesday against the closing price of the previous session at ₹829.65.
Lupin stock surges on robust sales in March quarter
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
Lupin shares dip 4% on US FDA observations for Pithampur unit
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Lupin recalls blood pressure tablets in U.S.; stock up 3%
Lupin Pharmaceuticals Inc., the U.S. arm of the drug major, is voluntarily recalling four lots of Quinapril Tablets due to the presence of nitrosamine impurity.
What’s behind Indian pharma cos’ global acquisition spree
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
Lupin shares rise 4% on nod for Mirabegron tablets
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.